Siponimod reduces risk of disability progression by 21%

Mayzent is an oral treatment for relapse remitting MS and active secondary progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:
Contact MSUK

Siponimod reduces risk of disability progression by 21%

Post by MSUK » Tue May 09, 2017 12:15 am

Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent, over a three month period...Read more - http://www.ms-uk.org/siponimod-reduces- ... ent-090517
MS-UK - http://www.ms-uk.org/
Top
User avatar
NHE
Volunteer Moderator
Posts: 5315
Joined: Sat Nov 20, 2004 3:00 pm
Contact:
Contact NHE

Re: Siponimod reduces risk of disability progression by 21%

Post by NHE » Sat Apr 27, 2019 2:53 pm

MSUK wrote: ↑
Tue May 09, 2017 12:15 am
 Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent.
That sounds good. However, it's a relative percentage reduction. The actual data plot doesn't look that impressive.


Image
Top
Zyklon
Family Elder
Posts: 339
Joined: Sun Apr 16, 2017 12:45 pm
Location: Turkey

Re: Siponimod reduces risk of disability progression by 21%

Post by Zyklon » Sat Apr 27, 2019 4:27 pm

I agree with NHE. Not much improvement and lots of possible side effects.
Pain! You made me a, you made me a believer, believer
Pain! You break me down, you build me up, believer, believer
Pain! Oh let the bullets fly, oh let them rain
My life, my love, my drive, it came from... Pain!
Top
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Mayzent (Siponimod)”